Company news

Amplia Therapeutics Ltd. news in 2022

Amplia Therapeutics Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Letter to Shareholders End of Year Summary and 2023 Plans

December 19, 2022

Appendix 4D and Financial Report Half Year ended 30 Sep 22

November 17, 2022

Amplia Appoints Dr Christopher Burns CEO & Managing Director

November 6, 2022

Quarterly Activities and Cashflow Reports - Sep 2022 Qtr

October 27, 2022

AMP886 Activity in Acute Myeloid Leukemia

October 2, 2022

CEO Resignation

September 11, 2022

Amplia Receives $1.8m R&D Tax Incentive

August 30, 2022

CEO & Managing Director Presentation to AGM

August 25, 2022

First Patient Recruited to ACCENT Trial in Pancreatic Cancer

August 2, 2022

Quarterly Activities and Cashflow Reports - June 2022 Qtr

July 28, 2022

AMP945 Shows Efficacy in Model of Lung Fibrosis

June 1, 2022

Preliminary Final Report and Annual Report YE 31 March 2022

May 29, 2022

Amplia Receives Second Ethics Clearance for Phase 2 Trial

May 12, 2022

AMP945 Pre-IND Meeting Outcome

May 8, 2022

Quarterly Activities and Cashflow Reports - March 2022 Qtr

April 19, 2022

Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients

April 6, 2022

AMP945 Improves Survival in Human Pancreatic Cancer Model

February 16, 2022

Quarterly Activities and Cashflow Reports - Dec 2021 Qtr

January 23, 2022

Amplia Completes Manufacture of AMP945 for Planned Trials

January 12, 2022

Decks in 2022